MVRBF - Medivir starts dosing in mid-stage study of fostrox/Lenvima combo for liver cancer
2023-03-14 05:42:41 ET
- Medivir ( OTC:MVRBF ) said the first patient with liver cancer started treatment with its drug fostroxacitabine bralpamide (fostrox) in combination with Eisai's ( OTCPK:ESALF ) ( OTCPK:ESAIY ) Lenvima in phase 2a trial.
- In the Swedish company's ongoing phase 1b/2a trial, fostrox is given in combination with two other drugs, either with Lenvima or with Merck's Keytruda.
- The study is evaluating the therapy in patients with hepatocellular carcinoma (HCC) for whom current first- or second-line therapy has proven ineffective or is not tolerable. The trial is expected to enroll up to 30 patients with HCC at sites in the U.K., Spain and South Korea.
- The company said preliminary results from phase 1b for fostrox in combination with Lenvima were positive with a good safety and tolerability profile and no dose-limiting toxicity was seen.
- Meanwhile, the second combination group where fostrox is given with Keytruda, the phase 1b dose escalation is still ongoing, according to Medivir.
For further details see:
Medivir starts dosing in mid-stage study of fostrox/Lenvima combo for liver cancer